1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Boston Scientific Corporation

Boston Scientific Corporation

BSX.F
Boston Scientific Corporationundefined flagFrankfurt Stock Exchange
39.30
EUR
-0.16
- -
58.41BMarket Cap
Boston Scientific Corporation
BSX.F
(Frankfurt Stock Exchange)

Recent

price

39.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
5.14
5.05
5.15
5.33
5.57
5.57
6.18
6.6
7.11
7.71
7
8.36
8.87
9.8
11.38
13.56
13.91
Revenue per Share
-0.7
0.29
-2.89
-0.09
-0.09
-0.18
0.26
0.08
1.21
3.38
-0.08
0.69
0.45
1.08
1.26
1.96
2.4
Basic EPS, GAAP
0.03
0.46
0.73
0.61
0.74
0.13
0.5
0.71
-0.13
0.88
0.7
0.93
0.64
1.17
1.61
2.3
2.22
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.02
0.04
0.04
0.02
- -
- -
- -
Dividend per Share
-3.17
-2.89
-6
-6.38
-6.55
-6.64
-6.31
-6.11
-5.02
-1.61
-1.67
-0.97
-0.51
0.58
1.83
3.77
4.67
Book Value per Share
-3.45
-3.23
-3.83
-3.81
-3.81
-4.73
-4.29
-4.25
-4.02
-3.01
-0.38
-1.04
-0.87
-0.59
-1.2
-0.56
0.34
Tangible Book Value per Share
1,518
1,509
1,407
1,341
1,324
1,341
1,358
1,370
1,381
1,392
1,417
1,422
1,430
1,453
1,472
1,480
1,482
Basic Weighted Avg Shares
7,806
7,622
7,249
7,143
7,380
7,477
8,386
9,048
9,823
10,735
9,913
11,888
12,682
14,240
16,747
20,074
20,615
Sales/Revenue/Turnover
12.68
12.96
12.84
12.38
12.22
13.24
15.73
16.92
16.89
16.21
6.9
15.34
16.04
16.97
17.93
19.78
19.92
Operating Margin (%)
816
717
683
689
725
769
815
844
894
1,011
1,123
1,093
1,136
1,196
1,269
1,368
1,394
Depreciation Expense
-1,065
441
-4,068
-121
-119
-239
347
104
1,671
4,700
-82
1,041
698
1,593
1,854
2,898
3,565
Net Income, GAAP
- -
31.31
- -
- -
- -
- -
- -
88.75
- -
- -
- -
3.35
38.83
19.8
19.11
14.56
4.89
Effective Tax Rate (%)
-13.64
5.79
-56.12
-1.69
-1.61
-3.2
4.14
1.15
17.01
43.78
-0.83
8.76
5.5
11.19
11.07
14.44
17.29
Profit Margin (%)
1,006
1,298
1,250
1,187
760
1,041
-348
-1,832
-1,257
-167
3,013
2,043
1,957
1,581
521
3,355
4,113
Working Capital
4,934
4,257
4,252
4,237
3,841
5,674
5,420
3,777
4,803
8,861
9,526
9,190
9,262
8,961
8,968
11,137
10,988
LT Debt
11,296
11,353
6,870
6,539
6,457
6,320
6,733
7,012
8,726
13,877
15,326
16,622
17,573
19,530
22,003
24,472
26,104
Total Equity
- -
4.21
- -
- -
- -
- -
- -
1.4
- -
- -
- -
6.9
4.68
6.91
7.83
9.88
10.94
Return on Invested Capital (%)
- -
241.07
- -
- -
- -
- -
- -
-4.42
- -
- -
- -
17.97
11.86
18.89
17.4
20.7
23.34
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
105.16
70.02
69.27
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
483
299
41
LT Borrowings
10,993
11,012
10,864
LT Finance Leases
570
125
124
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,482
1,483
1,486
Market Capitalization
143,853
141,872
92,489

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
8,035
8,794
8,684
Cash, Cash Equivalents & STI
1,275
1,965
1,453
Accounts Receivable, Net
2,828
2,926
3,027
Inventories
2,921
2,943
3,117
Total Current Liabilities
5,328
5,439
4,571
Payables & Accruals
4,005
4,345
3,655
ST Debt
483
299
41
Deferred Revenue
309
313
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.38%
9.84%
11.22%
Free Cash Flow
-43.11%
34.41%
43.93%
Net Income, GAAP
6.95%
-240.31%
56.31%
Sales/Revenue/Turnover
10.66%
15.27%
19.87%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,856
4,120
4,209
4,561
16,747
2025
4,663
5,061
5,065
5,286
20,074
2026
5,203
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.34
0.22
0.32
0.38
1.26
2025
0.46
0.54
- -
0.45
1.96
2026
0.9
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Shinva Medical Instrument Co., Ltd. (600587.SS)
EL.En. S.p.A. (ELEAF)
Carmat S.A. (ALCAR.PA)
Siemens Healthineers AG (SEMHF)
Hylsamex S.A. de CV (HYLSAMXB.MX)
Theralase Technologies Inc. (TLTFF)
Business
Boston Scientific Corporation Boston Scientific Corporation develops, manufactures, and markets innovative minimally invasive medical devices for interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, urology, gynecology, neuromodulation, oncology, respiratory, digestive, and neurological conditions; its core products include drug-eluting stents such as Taxus, implantable cardioverter-defibrillators like EMBLEM S-ICD, intravascular ultrasound systems, cardiac ablation controllers, embolization devices, guidewires, imaging systems, lasers for BPH and lithotripsy, defect closure devices, FFR and IVUS systems, OverStitch endoscopic systems, Orbera intragastric balloons, and WATCHMAN left atrial appendage closure devices. The company operates through MedSurg and Cardiovascular segments, serving physicians treating complex patient needs worldwide across 127 countries including the U.S., Europe, Middle East, Africa, Asia-Pacific, Latin America, and Canada, with world headquarters in Marlborough, Massachusetts, and regional centers in France, Singapore, Washington D.C., and Weston, Florida. Founded in 1979 by John Abele and Peter Nicholas as a holding company for Medi-Tech, Inc., Boston Scientific employs 53,000 people and invests $1.6 billion annually in R&D, launching approximately 100 new products in 2024 while generating $16.7 billion in net sales. Recent strategic expansions include the $3.7 billion acquisition of Axonics, Inc. completed in November 2024 to bolster urology offerings; agreements to acquire Bolt Medical for up to $664 million in January 2025 to enhance intravascular lithotripsy for coronary and peripheral artery disease; SoniVie Ltd. for $540 million in March 2025 to expand hypertension treatment via ultrasound renal denervation; and Nalu Medical, Inc. for approximately $533 million announced in October 2025, expected to close in the first half of 2026, adding micro-implantable peripheral nerve stimulation for chronic pain.

Company News

APIChatGPT